Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lally, E. T.
Right arrow Articles by Billings, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lally, E. T.
Right arrow Articles by Billings, P. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 272, Number 48, Issue of November 28, 1997 pp. 30463-30469

RTX Toxins Recognize a beta 2 Integrin on the Surface of Human Target Cells*

(Received for publication, September 15, 1997)

Edward T. Lally Dagger §, Irene R. Kieba Dagger , Atsushi Sato , Cecelia L. Green Dagger , Joel Rosenbloom Dagger , Jon Korostoff Dagger , Jian Fei Wang Dagger , Bruce J. Shenker Dagger , Susan Ortlepp par , Martyn K. Robinson par and Paul C. Billings Dagger

From the Dagger  Leon Levy Research Center for Oral Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6002, the   First Department of Oral Surgery, School of Dental Medicine University of Ohu, 31-1, Aza-Misumido, Tomita-cho, Koriyama-shi, Fukushima, 963, Japan, and par  Celltech Ltd., Slough SL1 4EN, United Kingdom

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Actinobacillus actinomycetemcomitans leukotoxin and Escherichia coli alpha -hemolysin are RTX toxins that kill human immune cells. We have obtained a monoclonal antibody (295) to a cell surface molecule present on toxin-sensitive HL60 cells that can inhibit cytolysis by both RTX toxins. Utilization of this monoclonal antibody for immunoaffinity purification of detergent-solubilized target cell membranes yielded two polypeptide chains of approximate molecular masses of 100 and 170 kDa. Microsequencing of tryptic peptides from the two proteins showed complete homology with CD11a and CD18, the two subunits of the beta 2 integrin, lymphocyte function-associated antigen 1 (LFA-1). Anti-CD11a and CD18 monoclonal antibodies also inhibited RTX toxin-mediated cytolysis. Direct binding experiments demonstrated the ability of an immobilized RTX to bind LFA-1 heterodimers present in a detergent lysate of human HL60 target cells. Transfection of CD11a and CD18 integrin genes into a cell line (K562) that is not sensitive to either RTX toxin resulted in LFA-1 expressing cells, KL/4, that were sensitive to both toxins. These experiments identify LFA-1 as a cell surface receptor that mediates toxicity of members of this family of pore-forming toxins.


INTRODUCTION

A paradigm emerging from studies of bacterial protein toxins is that target cell recognition is often the initial event of a multistep process ultimately leading to diverse mechanisms of cell death. For example, colicins (1) bind to various outer membrane proteins of Escherichia coli (2), Bacillus thuringiensis delta -endotoxin recognizes the brush border of insect gut cells (3), diphtheria toxin binds to a heparin-binding epidermal growth factor-like precursor (4), and the family of AB5 toxins (e.g. cholera toxin) bind to cell surface ganglioside lipids (5). Actinobacillus actinomycetemcomitans leukotoxin is a member of the RTX toxin family of pore-forming hemolysins/leukotoxins (6-11). Leukotoxin kills cells of the lymphocytic and monomyelocytic lineage of man and some higher nonhuman primates. The narrow host range of leukotoxin suggests that the toxin may bind a specific cell surface receptor. However, no target cell receptors for RTX toxins have yet to be identified. Both toxin-sensitive and several toxin-resistant cells (12) are capable of absorbing toxin from culture supernatants, indicating that simple adsorption of the toxin onto a cell membrane is not enough to cause cell death. The ability of these toxins to adhere to various cell surfaces also indicates that classical experiments designed to detect the presence of a receptor such as saturation of binding or inhibition of labeled toxin binding with excess unlabeled toxin will not be effective in detecting cell surface receptors for this family of toxins. We have employed an alternative approach to identify a cell surface molecule that mediates RTX toxin cytotoxicity.


MATERIALS AND METHODS

Production of Monoclonal Antibodies to HL60 Cell Surface Molecules

Balb/cJ female mice (Jackson Laboratories, Bar Harbor, ME) 12-16 weeks old were immunized intravenously with 2 × 107 HL60 cells, boosted on days 10, 20, and 30 with an equal number of cells and allowed to rest for 60 days. 3 days before fusion, the animals again received 2 × 107 HL60 cells intravenously. On the day of fusion, spleens were removed aseptically, and a single cell suspension was prepared with a loose fitting tissue homogenizer. The cells were washed once in Dulbecco's minimal essential medium, and the erythrocytes were lysed with 0.17 M ammonium chloride-Tris buffer. Spleen cells recovered in this manner had a viability of >95% as assessed by trypan blue exclusion. Sp2/0-Agl4 myeloma cells were mixed with spleen cells (1:10) and centrifuged. A 1-ml portion of 30% polyethylene glycol solution (PEG 1000; J. T. Baker Chemical Co., Phillipsburg, NJ) was slowly added to the cell pellet. The pellet was gently stirred, allowed to set for 1 min, and then dispersed by the addition of 50 ml of Dulbecco's minimal essential medium. After centrifugation, the cells were suspended in 30 ml of Kennett's HY medium (4.5 g/liter Dulbecco's minimal essential medium with high glucose, glutamine, 10% NCTC 109, 20% fetal bovine serum, 1% 0.15 mg/ml oxaloacetate, 0.05 mg/ml pyruvate, and 0.2 unit/ml bovine insulin) and 1% 5 mM hypoxanthine and 0.8 mM thymidine), and 0.1-ml portions were placed in 96-well tissue culture plates. The next day, an additional 0.1 ml of medium containing aminopterin (0.04 µM) was added to each well. Cells were fed every 3-4 days by drawing off 0.1 ml of spent medium. Clones were visible 7-9 days after the fusion, and when they covered approximately one-half of the bottom of the well, they were screened for their ability to inhibit RTX-mediated cytotoxicitv in the biological assay (13, 14).

Anti-integrin Monoclonal Antibodies

The anti-integrin mAbs1 used in the study were: TS1/18 (15), KIM127 (16), KIM185 (16), (IgG1,kappa ) antibodies that bind to CD18; 38 (17) (IgG2a,kappa ) and 25.3.1 (17) and TS1/22 (15) (IgG1,kappa ) antibodies that bind to CD11a; 44 (18), an (IgG1,kappa ) antibody that binds to CD11b; and 3.9 (19) an (IgG1,kappa ) antibody that binds to CD11c.

Analysis of RTX-mediated Target Cell Cytotoxicity

Leukotoxic activity of recombinant ltxA and hylA gene products was determined essentially as described previously (13). Briefly, E. coli containing ltxC and either ltxA or hylA in the pOTSNco12 plasmid were grown to late log phase, induced, and sonicated. The bacterial sonicate was incubated with target cells at 37 °C for 45 min. RTX-sensitive HL60 cells were cultured in RPMI 1640 and used as positive controls, whereas negative controls consisted of incubating target cells with: (i) tissue culture medium, (ii) sonicates from uninduced bacteria, or (iii) sonicates from induced bacteria that contained the pOTSNco12 plasmid without an insert. The cells were placed on ice, 100 µl of trypan blue (0.4%) were added, and surviving cells were counted in a hemocytometer. At least four fields were counted in triplicate and averaged for each dilution assayed. The percentage of lysis was calculated by dividing the number of surviving cells by the number of cells in the negative controls and subtracting from 100.

Staining and Analysis of Cells for Flow Cytometry

Prior to incubation with anti-integrin antibodies, HL60, KL/4, and K562 cells were washed twice in cold 1% BSA PBS and incubated with mouse IgG myeloma protein (10 µg; 30 min on ice) that was the same isotype as the anti-integrin antibody. Immunoglobulin bound during this incubation occurs via the F(c) receptor. After washing again in cold 1% BSA PBS, the cells were incubated with an anti-integrin antibody for 15 min, washed, and incubated for an additional 15 min with FITC-labeled goat anti-mouse IgG (Boehringer Mannheim Biochemical). The fluorescence level of a control group composed of cells, mouse IgG myeloma protein, and FITC-labeled goat anti-mouse IgG represented the background staining due to Fc-bound Ig. The fluorescence level of our experimental groups were then gated on the control group to determine the amount of anti-integrin antibody bound on the cells. After incubations, cells were washed, fixed in 2% paraformaldehyde, and stored at 4 °C until analysis. 5000-10000 cells were read per sample on a FACStar PlusTM (ABI, Mountain View CA) flow cytometer.

Purification and Analysis of Target Cell Surface Proteins

HL60 cells were pelleted (2000 × g, 10 min, 4 °C) and washed with PBS, and the resulting pellet was resuspended in lysis buffer (40 mM NaHCO3, pH 7.5, 200 mM NaCl, 0.5% CHAPS, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 5 µg/ml pepstatin). The suspension was vortexed intermittently on ice for 30 min and centrifuged (14,000 × g, 20 min, 4 °C), and the supernatant fraction was used for protein isolation. The supernatant was batch extracted with 0.5 ml of mAb295-activated Sepharose. The resin was pelleted by centrifugation (3000 × g, 10 min, 4 °C) and washed three times with 15 ml of wash buffer (10 mM phosphate, pH 8.0, 1 M NaCl, 0.5% Tween 20, 0.5% Triton X-100). Bound protein was eluted with 100 mM triethanolamine, pH 11.5, 100 mM NaCl, 0.5% CHAPS. The eluted protein was dialyzed against 10 mM Tris, pH 7.4, and concentrated by lyophilization.

The proteins were run on 8% SDS-PAGE gels using Bio-Rad reagents. Gel solutions were filtered (0.2 µm) and stored at 4 °C prior to use. Gels (including the stacker) were cast and allowed to stand for 24-48 h at room temperature (22 °C) prior to use, and 0.1 mM thioglycolate was added to the upper chamber buffer prior to electrophoresis. Eluted proteins were solubilized in 5 × buffer containing 0.5 M sucrose and heated at 37 °C for 15 min. After electrophoresis, proteins were transferred to a polyvinylidene difluoride membrane. Prior to transfer, polyvinylidene difluoride membrane was pre-wet in MeOH for 10 s and then in transfer buffer with 10% MeOH for 5 min. After transfer, the membrane was rinsed with Milli-Q® water three times for 5 min. The membrane was stained with Amido Black, and proteins of 100 and 170 kDa were cut from the membrane and digested with trypsin. The resultant tryptic fragments were separated by HPLC, and peptides from each protein were selected for sequencing.

Direct Binding of RTX Toxin and beta 2 Integrin Heterodimers

Purified A. actinomycetemcomitans leukotoxin (20) was dissolved in PBS (20 µg/ml) and incubated with <FR><NU>1</NU><DE>8</DE></FR>-inch polystyrene beads (10 beads/20 µg of toxin) in a 3-ml siliconized Vacutainer tube (no additives) with gentle rocking overnight at 4 °C. The beads were washed with PBS and incubated with 1 mg/ml BSA in PBS for 1 h to block the remaining sites. CHAPS extracts (10 µg of protein) of HL-60 cells were incubated with the derivatized beads for 15 h at 4 °C in PBS. After incubation, the beads were washed three times with PBST (PBS containing 0.1% Tween 20) followed by a final rinse in 10 mM Tris-HCl, pH 7.4. Bound protein was eluted from the beads using SDS gel loading buffer and size fractionated on 8-16% SDS gradient gels under nonreducing conditions. Proteins were transferred to a nitrocellulose membrane, and the membrane was blocked in PBS, 5% milk and subsequently incubated with anti-LFA-1 antibodies for 15 h at 4 °C. The membranes were washed three times with PBST and incubated with a goat anti-mouse HRP conjugate in PBS, 5% milk for 1 h at room temperature. The blots were washed with PBST and developed using chemiluminescent detection.

Transfection of K562 with beta 2 Integrin Genes

K562 transfectants (21) were produced by subcloning the CD11a and CD18 genes into a derivative of the expression vector EE6hCMV (22) carrying a G418 resistance marker.

Reverse Transcriptase Polymerase Chain Reaction

After transfection, the transcription of the integrin genes (23, 24) was confirmed by the reverse transcriptase-PCR using primers synthesized in our laboratory. Glyceraldehyde-3-phosphate dehydrogenase (GADPH), which is present in both normal and transfected cells, was used as a control gene (25). Messenger RNA was prepared from KL4 and K562 cell lines using the Quick Prep micro mRNA purification kit (Pharmacia 27-9255-01) followed by first strand cDNA synthesis using You-Prime First-Strand Beads (Pharmacia 27-9264-01) according to the manufacturer's instructions. Subsequent amplification was performed using a Perkin-Elmer 9600 Thermocycler and Ready To Go PCR beads (Pharmacia 27-9555-01) under the following conditions. The primers for PCR were: forward primer CD11a, GGGAATGACCTTGGCAACAGACCCCACAGAT; reverse primer CD11a, GGGTCTCCTGACTCTCCTTGGTCT; forward primer CD18, ATCCTGACTCCATTCGCTGC; reverse primer CD18, CTCGGTCTGAAACTGGTTGG; forward primer GADPH, CCACCCATGGCAAATTCCATGGCA; reverse primer GADPH, TCTAGACGGCAGGTCAGGTCCACC.

The samples were heated to 94 °C for 6 min 15 s followed by 30 cycles at 94 °C for 15 s, 55 °C for 15 s, and 72 °C for 15 s and finally an extension of 9 min 15 s at 72 °C. Southern blotting was performed using Gene Screen Plus hybridization transfer membrane (NEN Life Science Products NEF-986) according to the manufacturer's instructions. Internal oligomers (23, 24) were labeled using the ECL 3'-oligolabeling and detection system (Amersham Corp. RPN 2131). The internal probes for Southern blotting were: CD11a, CGCGACAGAGGTGTTCCGGGAGGAGC (expected PCR product = 610 bp); CD18, GGACCTCTCCTACTCCATGCTTGATGACCTCAGG (expected PCR product = 496 bp).


RESULTS

Identification and Analysis of a Monoclonal Antibody That Inhibits RTX-mediated Cytotoxicity

Initial experiments were designed to identify a monoclonal antibody that has specificity for a cell surface molecule on target cells and is capable of inhibiting RTX-mediated cytotoxicity. Balb/cJ mice were immunized with HL60 cells via the intravenous route. Spleens from immunized mice were removed and fused with Sp2/0-Ag14, a mouse myeloma cell line. Hybridoma culture supernatants were screened for their ability to inhibit HL60 cytotoxicity by two RTX toxins, E. coli alpha -hemolysin, and A. actinomycetemcomitans leukotoxin. Of 2,500 clones screened, one clone, mAb295 (IgG1,kappa ), was noted to be an efficient inhibitor of the cytotoxic activity of both toxins (Fig. 1A). Fluorescent cell sorting analysis demonstrated that the mAb295 antigen resides on the cell surface of human peripheral blood polymorphonuclear leukocytes, monocytes, and lymphocytes (Fig. 1B).


Fig. 1. Inhibition of RTX toxin-mediated cytolysis by mAb295 and cell surface expression of mAb295 reactive protein. A, HL60 cells were incubated with increasing concentrations of mAb295 for 45 min. An LD75 dose of either A. actinomycetemcomitans leukotoxin (bullet l) or E. coli alpha -hemolysin (open circle ) was then added to the tubes, and the cells were then incubated an additional 45 min. Control cells (A. actinomycetemcomitans leukotoxin (black-down-triangle ) or E. coli alpha -hemolysin (down-triangle)) that were incubated with toxin alone are also shown. Following this incubation, the cells were placed on ice, 100 µl of trypan blue (0.4%) was added, and surviving cells were counted in a hemocytometer. At least four fields were counted in triplicate and averaged for each dilution assayed. The results are expressed as the percentage of inhibition. B, FITC-conjugated mAb295 was incubated with peripheral blood leukocytes and analyzed by FACS. The results are plotted as relative cell number versus FITC fluorescence and are representative of three experiments; 104 cells were analyzed per sample. PMN polymorphonuclear.

[View Larger Version of this Image (26K GIF file)]


Cell Surface Molecule Recognized by an RTX-inhibiting Monoclonal Antibody Is a beta 2 Integrin

To identify the mAb295 antigen, HL60 cell membrane extracts were first solubilized with 0.5% CHAPS, passed through a CNBr Sepharose 4B-mAb295 affinity column (26), and then analyzed with SDS-PAGE. Examination of the gels revealed two proteins of relative molecular masses of 100 and 170 kDa had bound to the mAb affinity resin. (Fig. 2, lane 3). No evidence of these bands was noted when the same HL60 CHAPS lysate was passed over an affinity column with a control myeloma protein attached (Fig. 2, lane 4).


Fig. 2. Biochemical characterization of the mAb295 reactive protein. HL60 cell membranes were solubilized with detergent (0.5% CHAPS in 0.15 M NaCl) and passed over an mAb295-CNBr conjugated SepharoseTM 4B column. Bound proteins were eluted with 100 mM triethanolamine buffer, pH 11.5, separated on a 12% SDS-polyacrylamide gel, and stained with Coomassie Blue. Lane 1, molecular mass standards; lane 2, detergent solubilized HL60 membrane proteins; lane 3, eluate from a mAb295-CNBr conjugated SepharoseTM 4B column 170- and 100-kDa proteins are designated with arrows; lane 4, eluate from a control MOPC 21(IgG1kappa )-CNBr-conjugated SepharoseTM 4B column.

[View Larger Version of this Image (61K GIF file)]


Eluted proteins from a mAb295 affinity column were subjected to preparative SDS-PAGE and blotted onto polyvinylidene difluoride membranes. After staining with Amido Black, proteins of interest were cut from the blot and subjected to trypsin digestion. Peptides were separated by HPLC and sequenced by solid phase amino acid sequencing. Two tryptic peptides from the 170-kDa protein were sequenced and showed complete homology with sequences from CD11a, whereas three peptides from the 100-kDa band were sequenced and found to be identical to sequences of CD18 (Table I). The CD11a and CD18 polypeptides form the alpha  and beta  subunits, respectively, of a leukocyte-specific beta 2 integrin, LFA-1.

Table I. Amino acid sequences of tryptic peptides derived from 100- and 170-kDa proteins present in the eluate from a mAb295-Sepharose column

Eluates from the mAb295 immunoaffinity column were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes. Protein bands (100 and 170 kDa) were cut from the blots and digested with trypsin, and peptides isolated via HPLC for sequencing. Sequences were then used to query the protein data base, and homologous sequences were identified.

Protein Tryptic peptide Massa Sequence Homology

170 kDa 1 1583.8 /1583.9 AGYLGYTVTWLPSR CD11a (residues 401-414)
2 2734.3 /3205.5 FGEAITALTDINGDGLVDVAVGAPLEEQGAVY CD11a (residues 521-552)
100 kDa 1 1884.1 /1881.2 SAVGELSEDSSNVVHLIK CD18 (residues 332-349)
2 1810 /1810 LLVFATDDGFHFAGDGK CD18 (residues 250-266)
3 NDb VTLYLRPGQAAAFNVTFR CD18 (residues 95-112)

a Mass was determined by mass spectrometry/calculated.
b ND, not determined. Peptide was a secondary sequence recovered with peptide 1.

Anti-CD11a and anti-CD18 Monoclonal Antibodies Are Capable of Inhibiting RTX-mediated Cytotoxicity

Identification of LFA-1 as the molecule that is recognized by mAb295 led us to explore the possibility that anti-CD11 and anti-CD18 monoclonal antibodies might also inhibit RTX-mediated cytotoxicity. A panel of anti-LFA-1 monoclonal antibodies was screened to identify those inhibiting RTX toxin-mediated cytotoxicity (Fig. 3A). TS1/22, an anti-CD11a antibody, and three anti-CD18 antibodies (TS1/18, KIM127, and KIM185) were capable of inhibiting RTX cytolysis. The possibility that the experimental observations were due to Fc receptor binding was ruled out by incubating cells with an isotype-matched (IgG1,kappa ) control antibody, MOPC 21. If inhibition of RTX cytotoxicity was due to anti-integrin antibodies binding via the Fc receptor and not to the beta 2 integrin, then MOPC21 would be equally effective inhibiting target cell killing as the anti-integrin antibodies. This was not observed.


Fig. 3. Inhibition of RTX toxin cytotoxicity by CD11a and CD18 monoclonal antibodies. A, beta 2 integrin monoclonal antibodies inhibit RTX toxin cytotoxicity of either A. actinomycetemcomitans leukotoxin (square ) or E. coli alpha -hemolysin (black-square). B, HL60 cells were incubated with unlabeled TS1/22 (anti-CD11a) monoclonal antibody for 45 min and incubated with FITC-conjugated mAb295 for an additional 45 min and analyzed by FACS. Controls consisted of unlabeled cells and cells incubated with FITC-conjugated mAb295 alone. The results are plotted as relative cell number versus FITC fluorescence and are representative of three experiments; 10,000 cells were analyzed per sample.

[View Larger Version of this Image (15K GIF file)]


To determine the region of LFA-1 recognized by mAb295, antibodies (TS1/22, TS1/18, KIM127, and KIM185) that recognize CD11a-CD18 were used in a series of cross-blocking experiments. Of those tested, only TS1/22 (Fig. 3B), an antibody recognizing the 200-amino acid I domain of CD11a (27), inhibited mAb295 binding, an indication that the mAb295 epitope also resides on CD11a.

RTX Toxins Bind to LFA-1

Several mechanisms could account for inhibition of RTX-mediated cytotoxicity by anti-beta 2 integrin monoclonal antibodies. A likely explanation is steric hinderance. The monoclonal antibody then interferes with binding of the toxin to the same integrin heterodimer. Alternatively, the toxin does not bind to beta 2 integrins, but rather the interaction of antibody and integrin effect changes in the cell surface, rendering it impervious to toxin binding at a distal site. To resolve this issue, a series of experiments examining the ability of RTX toxins to bind directly to beta 2 integrins was initiated. Purified A. actinomycetemcomitans leukotoxin was passively adsorbed onto polystyrene beads, and additional protein binding was blocked by incubating the beads with BSA. The toxin beads were then incubated with a 0.5% CHAPS lysate from HL60 cells. Bound protein was eluted from the beads, run on SDS-PAGE under nonreducing conditions, blotted onto nitrocellulose, and incubated with either 25.3.1 (an anti-CD11a antibody) or KIM185 (an anti-CD18 antibody). The Western blot shows that CD11a (Fig. 4A, lane 3) and CD18 (Fig. 4A, lane 7) polypeptides are detected in the eluate from RTX toxin beads. Control beads coated with BSA alone showed no evidence of binding of either integrin unit (Fig. 4A, lanes 2 and 6). Furthermore, when 10 µg of soluble A. actinomycetemcomitans leukotoxin was added to the CHAPS lysate, the ability of the RTX toxin beads to bind either component of the LFA-1 heterodimer was completely abolished (Fig. 4A, lanes 4 and 8). To further assess binding specificity, we determined the ability of mAb295 to block LFA-1 toxin interaction (Fig. 4B). Preincubation of HL-60 lysates with mAb295 (10 µg/tube) diminished integrin binding to beads (Fig. 4B, lanes 4 and 8). No inhibition of binding was observed when the lysates were incubated with an equivalent amount of an isotype control antibody, MOPC21 (Fig. 4B, lanes 3 and 7).


Fig. 4. Direct binding of A. actinomycetemcomitans leukotoxin to LFA-1. A, HL60 cell membranes were solubilized with detergent (0.5% CHAPS in 0.15 M NaCl) and incubated with the A. actinomycetemcomitans-leukotoxin polystyrene beads for 15 h at 4 °C in PBS. Bound protein was eluted from the beads using SDS gel loading buffer and size fractionated on nonreducing 8-16% SDS gradient gels. Lanes 1 and 5, input protein from CHAPS detergent lysate of HL60 cells; lanes 2 and 6, eluate from control (BSA)-polystyrene beads; lanes 3 and 7, eluate from A. actinomycetemcomitans leukotoxin-polystyrene beads; lanes 4 and 8, eluate from an HL60 lysate which was incubated with soluble A. actinomycetemcomitans leukotoxin (10 µg/ml) prior to leukotoxin beads. Gels were blotted onto nitrocellulose membranes, and fluorographs were developed after incubation (15 h at 4 °C) with either 25.3.1 (anti-CD11a monoclonal antibody, lanes 1-4) or KIM185 (anti-CD18 monoclonal antibody, lanes 5-8). B, HL60 cell membranes were solubilized as described above and incubated with 10 µg of either mAb295 or MOPC 21 (2 h at 4 °C). The mixture was then incubated with the A. actinomycetemcomitans-leukotoxin polystyrene beads and size fractionated on nonreducing 8-16% SDS gradient gels as described above. Lanes 1 and 5, input protein from CHAPS detergent lysate of HL60 cells; lanes 2 and 6, eluate from A. actinomycetemcomitans leukotoxin-polystyrene beads; lanes 3 and 7, eluate from an HL60 lysate that was incubated with MOPC 21 (10 µg/ml) prior to incubation with leukotoxin beads; lanes 4 and 8, eluate from an HL60 lysate that was incubated with mAb295 (10 µg/ml) prior to incubation with leukotoxin beads.

[View Larger Version of this Image (26K GIF file)]


Characterization of Transfected K562 Cells

A transfected cell line was employed to further define the involvement of CD18 and CD11a genes in RTX toxin-mediated cytotoxicity. K562, a human erythroleukemia cell line that does not express detectable CD11a or CD18 was transfected with both CD11a and CD18 in a single plasmid. One of the transfected cell lines, KL/4, was shown to express both CD11a and CD18 genes using reverse transcriptase-PCR. Analysis of cDNA revealed the expected 610- and 496-bp PCR products for CD11a (Fig. 5, lane 1) and CD18 (Fig. 5, lane 2) genes in KL/4 cells. No signal for CD11a or CD18 was detected in mock transfected control K562/gen cells (Fig. 5, lanes 4 and 5). Both cell lines produced detectable levels of the control gene, GADPH (Fig. 5, lanes 3 and 6). The 610- and 496-bp PCR products amplified from KL/4 hybridized to internal sequence probes of CD11a (Fig. 5, lane a) and CD18 (Fig. 5, lane b), respectively.


Fig. 5. Analysis of the presence of CD11a and CD18 cDNA in KL/4 and K562 cells by reverse transcriptase-PCR. RNA were isolated, reverse transcribed, and amplified using primers described under "Materials and Methods" for KL/4 (lanes 1, 2, and 3) and K562/gen (lanes 4, 5, and 6). Lanes 1 and 4, CD11a primers (expected product 610 bp); lanes 2 and 5, CD18 primers (expected product 496 bp); and lanes 3 and 6, GADPH primers (expected product 598 bp). Blot, reaction products from lanes 1 and 2 were blotted onto nylon membranes and hybridized with CD11a (lane a) and CD18 (lane b) probes constructed from predicted internal sequences of the amplified DNA.

[View Larger Version of this Image (66K GIF file)]


FACS analysis of transfected KL/4 cells (Table II) demonstrated cell surface expression of CD11a and CD18 gene products, whereas no evidence of LFA-1 expression was observed on K562 cells. Fluorescence intensity levels of the two proteins appeared similar, indicating that production of the two proteins is comparable. In addition, the failure to demonstrate expression of either CD11b or CD11c chains demonstrate that LFA-1 is the only beta 2-integrin expressed on KL/4 cells. Functional characterization of the LFA-1 on cells (KL/4) has been described previously (21). Integrin expression by KL/4 cells appears to be in a low state of activation as determined by their inability to bind either ICAM-1 ligand or antibodies that recognize activation epitopes.

Table II. Expression of beta 2 integrin heterodimers in transfected K562 cells

FACS analysis of K562 cells and LFA-1 (KL/4)-transfected cells were stained with anti-beta 2 integrin antibodies. Antibodies were used at a concentration of 10 µg/ml, and staining was done at 4 °C. Results are shown as mean fluorescence.

MOPC 21 (control)a 38 (CD11a)b 44 (CD11b)b 3.9 (CD11c)b TS1/18 (CD18)c

K562 100 90 85 91 97
KL/4 (LFA-1) 60 517 53 51 486

a Sigma (catalog number M9269).
b R & D Systems (catalog numbers BCA1, BCA2, and BCA3).
c Endogen, Inc. (catalog number MA-1810).

Influence of beta 2 Integrin Gene Expression on the Susceptibility of Cells to RTX Toxins

K562 cells do not express beta 2 integrin gene products and are resistant to the lytic effects of E. coli alpha -hemolysin or A. actinomycetemcomitans leukotoxin (12). Further, K562/gen, a mock transfected K562 cell control, showed no evidence of susceptibility to either toxin (Fig. 6A). However, when K562 cells were transfected with CD11a and CD18 genes on the same plasmid, the resultant cell line (KL/4) was sensitive to both RTX toxins (Fig. 6A). The lethal effects of the RTX toxins could be ablated by preincubation of KL/4 cells with anti-CD11a monoclonal antibody mAb295 but not by MOPC21, an isotype matched control antibody.


Fig. 6. Effects of RTX toxin on K562 cells transfected with a beta 2 integrin heterodimer. A, A. actinomycetemcomitans leukotoxin (square ) or E. coli alpha -hemolysin (black-square) was incubated with KL/4, a cell line derived from K562 cells and transfected with CD11a-CD18 genes. In two groups, KL/4 cells were also incubated with either mAb295 or MOPC21 prior to toxin incubation. HL60 and K562/gen, a mock transfected control, served as positive and negative controls. Cell viability was assessed by trypan blue exclusion. B, electron photomicrographs of K562 (plate 1) and KL/4 (plate 2) cells after incubation with A. actinomycetemcomitans leukotoxin for 2 h. Cells treated with toxin showed loss of organelles and a prominent vacoulization of the cytoplasm (arrow).

[View Larger Version of this Image (37K GIF file)]


Transmission electron microscopy corroborated these experiments. K562 cells incubated with A. actinomycetemcomitans leukotoxin remain uniform in size and shape with prominent cellular organelles and are morphologically similar to untreated cells (Fig. 6B, plate 1). In contrast, KL/4 cells showed significant morphologic changes after toxin exposure. In half of the cells we noted an increase in size associated with vacuolated cytoplasm and degenerating organelles (Fig. 6B, plate 2, arrow). The remainder of KL/4 cells showed no evidence of RTX intoxication. KL/4 cells preincubated with mAb295 (10 µg/ml) were morphologically similar to untreated controls (data not shown).


DISCUSSION

We have used mAbs, direct binding, and gene transfection experiments to demonstrate that A. actinomycetemcomitans leukotoxin and E. coli alpha -hemolysin bind to CD11a-CD18 integrin (LFA-1) on human target cells. LFA-1 is found on most circulating leukocytes (lymphocytes, neutrophils, monocytes, and macrophages) but not on cells of nonhematopoetic origin. A member of the beta 2 integrin family, LFA-1, mediates leukocyte binding to endothelial cells via interactions with several members of the ICAM family (28), a function critical to leukocyte emigration during inflammatory responses. In addition, LFA-1 is involved in T cell functions such as adhesion of cytotoxic T cells to their target cells, antigen-induced T cell proliferation, and interactions between B cells and T cells.

The eukaryotic host cell membrane contains many molecules that could provide an adhesive function for invading pathogens, and several members of the integrin family have been shown to serve as targets for a variety of virulence determinants (29). CD11b-CD18 (MAC-1), a beta 2 integrin that binds the C3bi complement component, is used by several pathogens. Microorganisms that bind to MAC-1 are taken into the immune cell by the integrin and bypass powerful killing mechanisms, such as H2O2 or oxygen free radicals, associated with internalization by the phagocytic pathway (30). Unlike other beta 2 integrins, LFA-1 does not undergo endocytosis (31). The current study demonstrates a unique interaction whereby RTX toxins in which a beta 2 integrin is utilized destroy host immune cells rather than facilitate microbial internalization.

Our results demonstrating direct binding of A. actinomycetemcomitans leukotoxin to the LFA-1 heterodimer (Fig. 4) supports the mAb studies (Fig. 3) in identifying this integrin as a receptor for RTX toxins. Toxin-coated polystyrene beads bound both CD11a and CD18 subunits when analyzed by Western blotting. Furthermore, the fluorographs provided several interesting insights into the toxin-integrin interaction. The anti-CD18 antibody detected a primary band at 100 kDa and a smaller band at 90 kDa. The presence of the two beta 2 integrin species has been described previously (32, 33) and represents the mature polypeptide and precursor of the beta  chain. It appears that the leukotoxin is able to bind to LFA-1 molecules containing the precursor form of CD18. Examination of the fluorograph produced with anti-CD11a antibody showed relatively small amounts of alpha L chain present in the eluate from the toxin beads when compared with staining of the input protein. Additional experiments are required to determine if this observation represents preferential binding of CD18 molecules to the beads, inefficient elution of CD11a from the toxin beads, or partial denaturation of CD11a during binding, elution, or electrophoresis such that antibody reactivity is diminished.

The identification of an integrin receptor as the receptor for RTX toxins necessitates consideration of the role that molecular conformation may be playing in the toxin-target cell interaction. A feature of many integrins is their capacity to undergo stimulus-induced conformational changes that lead to increased ligand binding. Although the mechanism for such conformational changes is not currently understood, a variety of stimuli can produce increased integrin/ligand interactions (34) through modulation of the conformational state of the integrin (16). The affinity changes associated with LFA-1 activation appear to be complex and involve at least three conformational states (35). Thus, it is possible that different activation states (36, 37) could alter sensitivity to RTX toxins. The current studies suggest that the activation state of the integrin may influence the integrin-toxin interaction, because LFA-1 expressed on KL/4 cells is in a low activation state (21). KL/4 cells are less sensitive than HL60 to both RTX toxins when compared with HL60 cells under the same conditions (Fig. 6A). Supporting the low state of reactivity are the observations that the cells do not bind either ICAM-1 or antibodies that have been shown to recognize activation epitopes. We are currently determining if the differences in toxin sensitivity we observed are due to an unfavorable integrin binding state in KL/4 cells or due to differences unrelated to LFA-1 expression.

Regardless of the effect that integrin activation states may have on toxin-target cell interactions, our results demonstrate that RTX toxins do not bind in a manner homologous to the LFA-1-ICAM-1 interaction. KIM 127 (Fig. 3A) inhibited the target cell killing of both RTX toxins. Previous studies (21) have shown that binding of KIM 127 to cells activates LFA-1 function by increasing receptor binding to its ligand, ICAM-1. If RTX toxins did bind to LFA-1 at the canonical ICAM-1 binding site, we would expect KIM127-treated cells to have increased sensitivity to both toxins. Furthermore, failure of soluble ICAM-1 to inhibit RTX cytolysis, indicates that RTX toxins recognize regions of LFA-1 not involved in ligand binding.2

RTX toxins are subdivided into two classes based upon their target cell specificity. A. actinomycetemcomitans leukotoxin kills a narrow range of target cell types including lymphoid cells and granulocytes from man and certain primates (38, 39). The distribution pattern of CD11a-CD18 coincides with the range of cells susceptible to A. actinomycetemcomitans leukotoxin. In contrast, E. coli alpha -hemolysin is an RTX hemolysin that is toxic to a wide range of cell types such as red blood cells found in many species, chicken embryo fibroblasts, rabbit granulocytes, and mouse fibroblasts (3T3 cells) (40). In the present experiments, the finding that anti-CD11a and CD18 monoclonal antibodies inhibited both toxins suggests that expression of LFA-1 was sufficient for killing. However, the capacity of E. coli alpha -hemolysin to kill a wider range of cells may reside in its ability to bind cell surface molecules other than LFA-1. We are currently exploring this possibility.

The function that cell surface receptor molecules play in the pathogenesis of other bacterial toxins provides important paradigms in attempting to understand the RTX toxin receptor (1, 3-5). Recognition of cell surface molecules by RTX toxins represents the crucial component of a complex multi-step process in which the toxin transits from an aqueous to an amphipathic form. Bacterial protein toxins must be soluble in aqueous solutions while maintaining a capacity to interact within the hydrophobic environment of biological membranes. To achieve this dichotomous existence, toxins are organized into domains, and these regions are folded in such a way that the region of the toxin ultimately interacting with the cell membrane is internalized when the protein is in its aqueous form (41). Although there is a natural energy barrier that resists unfolding, toxin binding to LFA-1 could provide a very efficient mechanism to lower this barrier and catalyze a partial unfolding of the molecule leading to exposure of sequestered hydrophobic residues resulting in a membrane-inserted pore structure.

In conclusion, our results show that a member of the beta 2-integrin family, LFA-1, is a cell surface receptor for RTX toxins on human target cells. The ability of beta 2 integrin monoclonal antibodies to inhibit cell killing by RTX toxins and of beta 2 integrin gene expression to convert a toxin-insensitive cell to a toxin-sensitive one provide strong support for hypotheses linking beta 2 integrins to RTX-mediated cytotoxicity. Diapedesis toward sites of infection caused by either A. actinomycetemcomitans or uropathogenic E. coli requires participation of the CD11-CD18 adhesion complex. The ability of these pathogens to utilize these critical cell adhesion molecules to destroy host immune cells at mucosal sites would thus allow microbial colonization to proceed unabated. Continued study of the mechanisms involved in RTX toxin cytotoxicity will facilitate a further understanding of the biology of this interesting group of toxins and could lead to improved diagnostic and therapeutic applications.


FOOTNOTES

*   This work was supported by Grants 2 RO1 DE09517-06 and 5 P50 DE08239-10 from the NIDR, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Leon Levy Research Center for Oral Biology, University of Pennsylvania, 4010 Locust St., Philadelphia, PA 19104-6002. Tel.: 215-898-5913; Fax: 215-573-2050; E-mail: lally{at}toxin.dental.upenn.edu.
1   The abbreviations used are: mAb, monoclonal antibody; BSA, bovine serum albumin; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; LFA-1, lymphocyte function-associated antigen 1; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; HPLC, high pressure liquid chromatography; GADPH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pair(s); FACS, fluorescence-activated cell sorter; ICAM, intercellular adhesion molecule.
2   I. R. Kieba and E. T. Lally, unpublished data.

ACKNOWLEDGEMENTS

Flow cytometry analysis was performed at the University of Pennsylvania Cancer Center Flow Cytometry and Cell Sorting Shared Resource (supported in part by the Lucille B. Markey Trust and a National Cancer Institute Core Grant CA16520). We thank Sylvia Decker (electron microscopy) and Beatrice N. Engelsberg (SDS-PAGE) for expert assistance with the studies and Dr. James D. Lear (School of Medicine, University of Pennsylvania) for helpful comments and criticisms in preparation of the manuscript.


REFERENCES

  1. Pattus, F., Massotte, D., Wilmsen, H. U., Lakey, J., Tsernoglou, D., Tucker, A. X., and Parker, M. W. (1990) Experientia 46, 180-192 [Medline] [Order article via Infotrieve]
  2. Parker, M. W., Tucker, A. D., Tsernoglou, D., and Pattus, F. (1990) Trends Biochem. Sci. 15, 126-129 [CrossRef][Medline] [Order article via Infotrieve]
  3. Van Rie, J., Jansens, S., Hofte, H., Degheele, D., and Van Mellaert, H. (1990) Appl. Environ. Microbiol. 56, 1378-1385 [Abstract/Free Full Text]
  4. Van Rie, J., Jansens, S., Hofte, H., Degheele, D., and Van Mellaert, H. (1989) Eur. J. Biochem. 186, 239-247 [Medline] [Order article via Infotrieve]
  5. Merritt, E. A., and Hol, W. G. (1995) Curr. Opin. Struct. Biol. 5, 165-171 [CrossRef][Medline] [Order article via Infotrieve]
  6. Strathdee, C. A., and Lo, R. Y. (1989) J. Bacteriol. 171, 916-928 [Abstract/Free Full Text]
  7. Koronakis, V., Hughes, C., and Koronakis, E. (1993) Mol. Microbiol. 8, 1163-1175 [CrossRef][Medline] [Order article via Infotrieve]
  8. Lo, R. Y., Shewen, P. E., Strathdee, C. A., and Greer, C. N. (1985) Infect. Immun. 50, 667-671 [Abstract/Free Full Text]
  9. Lally, E. T., Kieba, I. R., Demuth, D. R., Rosenbloom, J., Golub, E. E., Taichman, N. S., and Gibson, C. W. (1989) Biochem. Biophys. Res. Commun. 159, 256-262 [CrossRef][Medline] [Order article via Infotrieve]
  10. Lian, C. J., Rosendal, S., and MacInnes, J. I. (1989) Infect. Immun. 57, 3377-3382 [Abstract/Free Full Text]
  11. Mobley, H. L., Chippendale, G. R., Swihart, K. G., and Welch, R. A. (1991) Infect. Immun. 59, 2036-2042 [Abstract/Free Full Text]
  12. Simpson, D. L., Berthold, P., and Taichman, N. S. (1988) Infect. Immun. 56, 1162-1166 [Abstract/Free Full Text]
  13. Lally, E. T., Golub, E. E., and Kieba, I. R. (1994) J. Biol. Chem. 269, 31289-31295 [Abstract/Free Full Text]
  14. Brogan, J. M., Lally, E. T., Poulsen, K., Kilian, M., and Demuth, D. R. (1994) Infect. Immun. 62, 501-508 [Abstract/Free Full Text]
  15. Sanchez-Madrid, F., Krensky, A. M., Ware, C. F., Robbins, E., Strominger, J. L., Burakoff, S. J., and Springer, T. A. (1982) Proc. Natl. Acad. Sci. U. S. A 79, 7489-7493 [Abstract/Free Full Text]
  16. Robinson, M. K., Andrew, D., Rosen, H., Brown, D., Ortlepp, S., Stephens, P. X., and Butcher, E. C. (1992) J. Immunol. 148, 1080-1085 [Abstract]
  17. Dransfield, I., and Hogg, N. (1989) EMBO J. 8, 3759-3765 [Medline] [Order article via Infotrieve]
  18. Third International Workshop and Conference on Human Leucocyte Differentiation Antigens (1987) Leucocyte Typing III: White Cell Differentiation Antigens, Oxford University Press, Oxford
  19. Hogg, N., Takacs, L., Palmer, D. G., Selvendran, Y., and Allen, C. (1986) Eur. J. Immunol. 16, 240-248 [Medline] [Order article via Infotrieve]
  20. Lear, J. D., Furblur, U. G., Lally, E. T., and Tanaka, J. C. (1995) Biochim. Biophys. Acta 1238, 34-41 [Medline] [Order article via Infotrieve]
  21. Ortlepp, S., Stephens, P. E., Hogg, N., Figdor, C. G., and Robinson, M. K. (1995) Eur. J. Immunol. 25, 637-643 [Medline] [Order article via Infotrieve]
  22. Stephens, P. E., and Cockett, M. I. (1989) Nucleic Acids Res. 17, 7110 [Free Full Text]
  23. Larson, R. S., Corbi, A. L., Berman, L., and Springer, T. (1989) J. Cell Biol. 108, 703-712 [Abstract/Free Full Text]
  24. Law, S. K., Gagnon, J., Hildreth, J. E., Wells, C. E., Willis, A. C., and Wong, A. J. (1987) EMBO J. 6, 915-919 [Medline] [Order article via Infotrieve]
  25. Reed, J. C., Krajewski, S., Kitada, S., and Miyashita, T. (1997) in The Lymphoid System (Herzenberg, L. A., Weir, D. M., Herzenberg, L. A., and Blackwell, C., eds), pp. 128.1-128.13, Blackwell Science, London
  26. Hughes, E. N., Engelsberg, B. N., and Billings, P. C. (1992) J. Biol. Chem. 267, 13520-13527 [Abstract/Free Full Text]
  27. Huang, C., and Springer, T. A. (1995) J. Biol. Chem. 270, 19008-19016 [Abstract/Free Full Text]
  28. Larson, R. S., and Springer, T. A. (1990) Immunol. Rev. 114, 181-217 [CrossRef][Medline] [Order article via Infotrieve]
  29. Isberg, R. R., and Tran Van Nhieu, G. (1994) Trends Microbiol. 2, 10-14 [CrossRef][Medline] [Order article via Infotrieve]
  30. Schnur, R. A., and Newman, S. L. (1990) J. Immunol. 144, 4765-4772 [Abstract]
  31. Bretscher, M. S. (1992) EMBO J. 11, 405-410 [Medline] [Order article via Infotrieve]
  32. Sanchez-Madrid, F., Simon, P., Thompson, S., and Springer, T. A. (1983) J. Exp. Med. 158, 586-602 [Abstract/Free Full Text]
  33. Huang, C., Lu, C., and Springer, T. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 3156-3161 [Abstract/Free Full Text]
  34. Hynes, R. O. (1992) Cell 69, 11-25 [CrossRef][Medline] [Order article via Infotrieve]
  35. Figdor, C. G., van Kooyk, Y., and Keizer, G. D. (1990) Immunol. Today 11, 277-280 [CrossRef][Medline] [Order article via Infotrieve]
  36. Kieffer, N., Fitzgerald, L. A., Wolf, D., Cheresh, D. A., and Phillips, D. R. (1991) J. Cell Biol. 113, 451-461 [Abstract/Free Full Text]
  37. Carrera, A. C., Rincon, M., Sanchez-Madrid, F., Lopez-Botet, M., and de Landazur, M. O. (1988) J. Immunol. 141, 1919-1924 [Abstract]
  38. Taichman, N. S., Shenker, B. J., Tsai, C. C., Glickman, L. T., Baehni, P. C., Stevens, R. X., and Hammond, B. F. (1984) J. Periodontal Res. 19, 133-145 [CrossRef][Medline] [Order article via Infotrieve]
  39. Taichman, N. S., Simpson, D. L., Sakurada, S., Cranfield, M., DiRienzo, J., and Slots, J. (1987) Oral Microbiol. Immunol. 2, 97-104 [Medline] [Order article via Infotrieve]
  40. Cavalieri, S. J., Bohach, G. A., and Snyder, I. S. (1984) Microbiol. Rev. 48, 326-343 [Free Full Text]
  41. van der Goot, F. G., Gonzalez-Manas, J. M., Lakey, J. H., and Pattus, F. (1991) Nature 354, 408-410 [CrossRef][Medline] [Order article via Infotrieve]

Volume 272, Number 48, Issue of November 28, 1997 pp. 30463-30469
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Infect. Immun.Home page
D. N. Atapattu, R. M. Albrecht, D. J. McClenahan, and C. J. Czuprynski
Dynamin-2-Dependent Targeting of Mannheimia haemolytica Leukotoxin to Mitochondrial Cyclophilin D in Bovine Lymphoblastoid Cells
Infect. Immun., November 1, 2008; 76(11): 5357 - 5365.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Morova, R. Osicka, J. Masin, and P. Sebo
RTX cytotoxins recognize {beta}2 integrin receptors through N-linked oligosaccharides
PNAS, April 8, 2008; 105(14): 5355 - 5360.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
L. M. Schaeffer, M. L. Schmidt, and D. R. Demuth
Induction of Aggregatibacter actinomycetemcomitans leukotoxin expression by IS1301 and orfA
Microbiology, February 1, 2008; 154(2): 528 - 538.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
T. Dileepan, S. C. Kachlany, N. V. Balashova, J. Patel, and S. K. Maheswaran
Human CD18 Is the Functional Receptor for Aggregatibacter actinomycetemcomitans Leukotoxin
Infect. Immun., October 1, 2007; 75(10): 4851 - 4856.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
D. N. Atapattu and C. J. Czuprynski
Mannheimia haemolytica Leukotoxin Binds to Lipid Rafts in Bovine Lymphoblastoid Cells and Is Internalized in a Dynamin-2- and Clathrin-Dependent Manner
Infect. Immun., October 1, 2007; 75(10): 4719 - 4727.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Sanchez-Magraner, A. R. Viguera, M. Garcia-Pacios, M. P. Garcillan, J.-L. R. Arrondo, F. de la Cruz, F. M. Goni, and H. Ostolaza
The Calcium-binding C-terminal Domain of Escherichia coli {alpha}-Hemolysin Is a Major Determinant in the Surface-active Properties of the Protein
J. Biol. Chem., April 20, 2007; 282(16): 11827 - 11835.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
L. E. Mansson, P. Kjall, S. Pellett, G. Nagy, R. A. Welch, F. Backhed, T. Frisan, and A. Richter-Dahlfors
Role of the Lipopolysaccharide-CD14 Complex for the Activity of Hemolysin from Uropathogenic Escherichia coli
Infect. Immun., February 1, 2007; 75(2): 997 - 1004.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. F. de Haar, P. S. Hiemstra, M. T. J. M. van Steenbergen, V. Everts, and W. Beertsen
Role of Polymorphonuclear Leukocyte-Derived Serine Proteinases in Defense against Actinobacillus actinomycetemcomitans
Infect. Immun., September 1, 2006; 74(9): 5284 - 5291.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Koschinski, H. Repp, B. Unver, F. Dreyer, D. Brockmeier, A. Valeva, S. Bhakdi, and I. Walev
Why Escherichia coli {alpha}-hemolysin induces calcium oscillations in mammalian cells--the pore is on its own
FASEB J, May 1, 2006; 20(7): 973 - 975.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Sanchez-Magraner, A. L. Cortajarena, F. M. Goni, and H. Ostolaza
Membrane Insertion of Escherichia coli {alpha}-Hemolysin Is Independent from Membrane Lysis
J. Biol. Chem., March 3, 2006; 281(9): 5461 - 5467.
[Abstract] [Full Text] [PDF]


Home page
JDRHome page
Y.-T.A. Teng
Protective and Destructive Immunity in the Periodontium: Part 2--T-cell-mediated Immunity in the Periodontium
Journal of Dental Research, March 1, 2006; 85(3): 209 - 219.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. Valeva, I. Walev, H. Kemmer, S. Weis, I. Siegel, F. Boukhallouk, T. M. Wassenaar, T. Chavakis, and S. Bhakdi
Binding of Escherichia coli Hemolysin and Activation of the Target Cells Is Not Receptor-dependent
J. Biol. Chem., November 4, 2005; 280(44): 36657 - 36663.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
T. Dileepan, M. S. Kannan, B. Walcheck, P. Thumbikat, and S. K. Maheswaran
Mapping of the Binding Site for Mannheimia haemolytica Leukotoxin within Bovine CD18
Infect. Immun., August 1, 2005; 73(8): 5233 - 5237.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
P. Kelk, R. Claesson, L. Hanstrom, U. H. Lerner, S. Kalfas, and A. Johansson
Abundant Secretion of Bioactive Interleukin-1{beta} by Human Macrophages Induced by Actinobacillus actinomycetemcomitans Leukotoxin
Infect. Immun., January 1, 2005; 73(1): 453 - 458.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
C. Martin, M.-A. Requero, J. Masin, I. Konopasek, F. M. Goni, P. Sebo, and H. Ostolaza
Membrane Restructuring by Bordetella pertussis Adenylate Cyclase Toxin, a Member of the RTX Toxin Family
J. Bacteriol., June 15, 2004; 186(12): 3760 - 3765.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-P. Weng, Y.-P. Lin, C.-I. Hsu, and J.-Y. Lin
Functional Domains of a Pore-forming Cardiotoxic Protein, Volvatoxin A2
J. Biol. Chem., February 20, 2004; 279(8): 6805 - 6814.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
N. Yamaguchi, C. Kubo, Y. Masuhiro, E. T. Lally, T. Koga, and S. Hanazawa
Tumor Necrosis Factor Alpha Enhances Actinobacillus actinomycetemcomitans Leukotoxin-Induced HL-60 Cell Apoptosis by Stimulating Lymphocyte Function-Associated Antigen 1 Expression{dagger}
Infect. Immun., January 1, 2004; 72(1): 269 - 276.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. J. Shenker, D. Besack, T. McKay, L. Pankoski, A. Zekavat, and D. R. Demuth
Actinobacillus actinomycetemcomitans Cytolethal Distending Toxin (Cdt): Evidence That the Holotoxin Is Composed of Three Subunits: CdtA, CdtB, and CdtC
J. Immunol., January 1, 2004; 172(1): 410 - 417.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. Mitchell, L. Gao, and D. R. Demuth
Positive and Negative cis-Acting Regulatory Sequences Control Expression of Leukotoxin in Actinobacillus actinomycetemcomitans 652
Infect. Immun., October 1, 2003; 71(10): 5640 - 5649.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
P. Kelk, A. Johansson, R. Claesson, L. Hanstrom, and S. Kalfas
Caspase 1 Involvement in Human Monocyte Lysis Induced by Actinobacillus actinomycetemcomitans Leukotoxin
Infect. Immun., August 1, 2003; 71(8): 4448 - 4455.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. Cortajarena, F. M. Goni, and H. Ostolaza
A Receptor-binding Region in Escherichia coli{alpha}-Haemolysin
J. Biol. Chem., May 23, 2003; 278(21): 19159 - 19163.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
K. P. Fong, L. Gao, and D. R. Demuth
luxS and arcB Control Aerobic Growth of Actinobacillus actinomycetemcomitans under Iron Limitation
Infect. Immun., January 1, 2003; 71(1): 298 - 308.
[Abstract] [Full Text] [PDF]


Home page
J Med MicrobiolHome page
B. HENDERSON, M. WILSON, L. SHARP, and J. M. WARD
Actinobacillus actinomycetemcomitans
J. Med. Microbiol., December 1, 2002; 51(12): 1013 - 1020.
[Full Text] [PDF]


Home page
Plant Physiol.Home page
S. W. Meinhardt, W. Cheng, C. Y. Kwon, C. M. Donohue, and J. B. Rasmussen
Role of the Arginyl-Glycyl-Aspartic Motif in the Action of Ptr ToxA Produced by Pyrenophora tritici-repentis
Plant Physiology, November 1, 2002; 130(3): 1545 - 1551.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. S. Deshpande, T. C. Ambagala, A. P. N. Ambagala, M. E. Kehrli Jr., and S. Srikumaran
Bovine CD18 Is Necessary and Sufficient To Mediate Mannheimia (Pasteurella) haemolytica Leukotoxin-Induced Cytolysis
Infect. Immun., September 1, 2002; 70(9): 5058 - 5064.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
F. Leite, S. O'Brien, M. J. Sylte, T. Page, D. Atapattu, and C. J. Czuprynski
Inflammatory Cytokines Enhance the Interaction of Mannheimia haemolytica Leukotoxin with Bovine Peripheral Blood Neutrophils In Vitro
Infect. Immun., August 1, 2002; 70(8): 4336 - 4343.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. C. Billings, J. C. Whitbeck, C. S. Adams, W. R. Abrams, A. J. Cohen, B. N. Engelsberg, P. S. Howard, and J. Rosenbloom
The Transforming Growth Factor-beta -inducible Matrix Protein beta ig-h3 Interacts with Fibronectin
J. Biol. Chem., July 26, 2002; 277(31): 28003 - 28009.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
S. L. G. Cirillo, L. Yan, M. Littman, M. M. Samrakandi, and J. D. Cirillo
Role of the Legionella pneumophila rtxA gene in amoebae
Microbiology, June 1, 2002; 148(6): 1667 - 1677.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Amino, R. M. Martins, J. Procopio, I. Y. Hirata, M. A. Juliano, and S. Schenkman
Trialysin, a Novel Pore-forming Protein from Saliva of Hematophagous Insects Activated by Limited Proteolysis
J. Biol. Chem., February 15, 2002; 277(8): 6207 - 6213.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
K. P. Fong, W. O. Chung, R. J. Lamont, and D. R. Demuth
Intra- and Interspecies Regulation of Gene Expression by Actinobacillus actinomycetemcomitans LuxS
Infect. Immun., December 1, 2001; 69(12): 7625 - 7634.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
W. Thomas, Z. K. Ascott, D. Harmey, L. W. Slice, E. Rozengurt, and A. J. Lax
Cytotoxic Necrotizing Factor from Escherichia coli Induces RhoA-Dependent Expression of the Cyclooxygenase-2 Gene
Infect. Immun., November 1, 2001; 69(11): 6839 - 6845.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Jeyaseelan, M. S. Kannan, R. E. Briggs, P. Thumbikat, and S. K. Maheswaran
Mannheimia haemolytica Leukotoxin Activates a Nonreceptor Tyrosine Kinase Signaling Cascade in Bovine Leukocytes, Which Induces Biological Effects
Infect. Immun., October 1, 2001; 69(10): 6131 - 6139.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. J. Shenker, R. H. Hoffmaster, A. Zekavat, N. Yamaguchi, E. T. Lally, and D. R. Demuth
Induction of Apoptosis in Human T Cells by Actinobacillus actinomycetemcomitans Cytolethal Distending Toxin Is a Consequence of G2 Arrest of the Cell Cycle
J. Immunol., July 1, 2001; 167(1): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
P. Guermonprez, N. Khelef, E. Blouin, P. Rieu, P. Ricciardi-Castagnoli, N. Guiso, D. Ladant, and C. Leclerc
The Adenylate Cyclase Toxin of Bordetella pertussis Binds to Target Cells via the {{alpha}}M{beta}2 Integrin (CD11b/CD18)
J. Exp. Med., April 30, 2001; 193(9): 1035 - 1044.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. L. G. Cirillo, L. E. Bermudez, S. H. El-Etr, G. E. Duhamel, and J. D. Cirillo
Legionella pneumophila Entry Gene rtxA Is Involved in Virulence
Infect. Immun., January 1, 2001; 69(1): 508 - 517.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
F. Leite, J. F. Brown, M. J. Sylte, R. E. Briggs, and C. J. Czuprynski
Recombinant Bovine Interleukin-1beta Amplifies the Effects of Partially Purified Pasteurella haemolytica Leukotoxin on Bovine Neutrophils in a beta 2-Integrin-Dependent Manner
Infect. Immun., October 1, 2000; 68(10): 5581 - 5586.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. J. Shenker, R. H. Hoffmaster, T. L. McKay, and D. R. Demuth
Expression of the Cytolethal Distending Toxin (Cdt) Operon in Actinobacillus actinomycetemcomitans: Evidence That the CdtB Protein Is Responsible for G2 Arrest of the Cell Cycle in Human T Cells
J. Immunol., September 1, 2000; 165(5): 2612 - 2618.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. K. Highlander, N. D. Fedorova, D. M. Dusek, R. Panciera, L. E. Alvarez, and C. Rinehart
Inactivation of Pasteurella (Mannheimia) haemolytica Leukotoxin Causes Partial Attenuation of Virulence in a Calf Challenge Model
Infect. Immun., July 1, 2000; 68(7): 3916 - 3922.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H.-Y. Lee, M. E. Kehrli Jr., K. A. Brogden, J. M. Gallup, and M. R. Ackermann
Influence of beta 2-Integrin Adhesion Molecule Expression and Pulmonary Infection with Pasteurella haemolytica on Cytokine Gene Expression in Cattle
Infect. Immun., July 1, 2000; 68(7): 4274 - 4281.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
S. L. G. Cirillo, J. Lum, and J. D. Cirillo
Identification of novel loci involved in entry by Legionella pneumophila
Microbiology, June 1, 2000; 146(6): 1345 - 1359.
[Abstract] [Full Text]


Home page
Infect. Immun.Home page
S. Jeyaseelan, S. L. Hsuan, M. S. Kannan, B. Walcheck, J. F. Wang, M. E. Kehrli, E. T. Lally, G. C. Sieck, and S. K. Maheswaran
Lymphocyte Function-Associated Antigen 1 Is a Receptor for Pasteurella haemolytica Leukotoxin in Bovine Leukocytes
Infect. Immun., January 1, 2000; 68(1): 72 - 79.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
Y. Sun, K. D. Clinkenbeard, L. A. Cudd, C. R. Clarke, and P. A. Clinkenbeard
Correlation of Pasteurella haemolytica Leukotoxin Binding with Susceptibility to Intoxication of Lymphoid Cells from Various Species
Infect. Immun., December 1, 1999; 67(12): 6264 - 6269.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
M. Braun, P. Kuhnert, J. Nicolet, A. P. Burnens, and J. Frey
Cloning and Characterization of Two Bistructural S-Layer-RTX Proteins from Campylobacter rectus
J. Bacteriol., April 15, 1999; 181(8): 2501 - 2506.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
B. J. Shenker, T. McKay, S. Datar, M. Miller, R. Chowhan, and D. Demuth
Actinobacillus actinomycetemcomitans Immunosuppressive Protein Is a Member of the Family of Cytolethal Distending Toxins Capable of Causing a G2 Arrest in Human T Cells
J. Immunol., April 15, 1999; 162(8): 4773 - 4780.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
W. Lin, K. J. Fullner, R. Clayton, J. A. Sexton, M. B. Rogers, K. E. Calia, S. B. Calderwood, C. Fraser, and J. J. Mekalanos
Identification of a Vibrio cholerae RTX toxin gene cluster that is tightly linked to the cholera toxin prophage
PNAS, February 2, 1999; 96(3): 1071 - 1076.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. Korostoff, J. F. Wang, I. Kieba, M. Miller, B. J. Shenker, and E. T. Lally
Actinobacillus actinomycetemcomitans Leukotoxin Induces Apoptosis in HL-60 Cells
Infect. Immun., September 1, 1998; 66(9): 4474 - 4483.
[Abstract] [Full Text] [PDF]


Home page
Microbiol. Mol. Biol. Rev.Home page
P. Stanley, V. Koronakis, and C. Hughes
Acylation of Escherichia coli Hemolysin: A Unique Protein Lipidation Mechanism Underlying Toxin Function
Microbiol. Mol. Biol. Rev., June 1, 1998; 62(2): 309 - 333.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. B. Lim, C. R. B. Walker, L. Guo, S. Pellett, J. Shabanowitz, D. F. Hunt, E. L. Hewlett, A. Ludwig, W. Goebel, R. A. Welch, et al.
Escherichia colialpha -Hemolysin (HlyA) Is Heterogeneously Acylated in Vivo with 14-, 15-, and 17-Carbon Fatty Acids
J. Biol. Chem., November 17, 2000; 275(47): 36698 - 36702.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. Cortajarena, F. M. Goni, and H. Ostolaza
Glycophorin as a Receptor for Escherichia colialpha -Hemolysin in Erythrocytes
J. Biol. Chem., April 13, 2001; 276(16): 12513 - 12519.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lally, E. T.
Right arrow Articles by Billings, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lally, E. T.
Right arrow Articles by Billings, P. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement